Adolescent Obstructive Hypertrophic Cardiomyopathy
BMYBristol-Myers SquibbCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Camzyos/Mavacamten (MYK-461) (Myosin Inhibitor) in Adolescent Obstructive Hypertrophic Cardiomyopathy. The expected timing is based on the latest available company guidance and may change.
01/11/26:- SCOUT-HCM Ph3 in adolescent oHCM met primary endpoint; full results at future congress, regulatory discussions planned. 03/20/26:- Full Phase 3 SCOUT-HCM results at ACC 2026 on March 29, 2026. 05/29/26:- FDA accepted priority sNDA for adolescent oHCM; PDUFA set for September 30, 2026.
Verification
Confirm timing and program details against the company announcement or filing.